231 related articles for article (PubMed ID: 31931150)
1. Characterisation and risk factor profiling of Pseudomonas aeruginosa urinary tract infections: pinpointing those likely to be caused by multidrug-resistant strains.
Tumbarello M; Raffaelli F; Peghin M; Losito AR; Chirico L; Giuliano G; Spanu T; Sartor A; Fiori B; Bassetti M
Int J Antimicrob Agents; 2020 Apr; 55(4):105900. PubMed ID: 31931150
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibilities and clinical characterization of Pseudomonas aeruginosa isolates from urinary tract infections.
Zhang X; Niu S; Zhang L
Urol Int; 2014; 93(4):464-9. PubMed ID: 24642393
[TBL] [Abstract][Full Text] [Related]
3. Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of Acinetobacter baumannii and Pseudomonas aeruginosa among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study.
Motbainor H; Bereded F; Mulu W
BMC Infect Dis; 2020 Jan; 20(1):92. PubMed ID: 32000693
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
5. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.
Tumbarello M; Repetto E; Trecarichi EM; Bernardini C; De Pascale G; Parisini A; Rossi M; Molinari MP; Spanu T; Viscoli C; Cauda R; Bassetti M
Epidemiol Infect; 2011 Nov; 139(11):1740-9. PubMed ID: 21226988
[TBL] [Abstract][Full Text] [Related]
6. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
Lodise TP; Miller CD; Graves J; Furuno JP; McGregor JC; Lomaestro B; Graffunder E; McNutt LA
Antimicrob Agents Chemother; 2007 Feb; 51(2):417-22. PubMed ID: 17158943
[TBL] [Abstract][Full Text] [Related]
7. Urinary tract infections caused by Pseudomonas aeruginosa among children in Southern Poland: Virulence factors and antibiotic resistance.
Pobiega M; Maciag J; Pomorska-Wesolowska M; Chmielarczyk A; Romaniszyn D; Ziolkowski G; Heczko PB; Wojkowska-Mach J; Bulanda M
J Pediatr Urol; 2016 Feb; 12(1):36.e1-6. PubMed ID: 26320394
[TBL] [Abstract][Full Text] [Related]
8. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.
Gudiol C; Albasanz-Puig A; Laporte-Amargós J; Pallarès N; Mussetti A; Ruiz-Camps I; Puerta-Alcalde P; Abdala E; Oltolini C; Akova M; Montejo M; Mikulska M; Martín-Dávila P; Herrera F; Gasch O; Drgona L; Paz Morales H; Brunel AS; García E; Isler B; Kern WV; Morales I; Maestro-de la Calle G; Montero M; Kanj SS; Sipahi OR; Calik S; Márquez-Gómez I; Marin JI; Gomes MZR; Hemmatti P; Araos R; Peghin M; Del Pozo JL; Yáñez L; Tilley R; Manzur A; Novo A; Carratalà J;
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015035
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of hospitalised patients with catheter-associated urinary tract infection in countries with a high rate of multidrug-resistance: the COMBACTE-MAGNET RESCUING study.
Gomila A; Carratalà J; Eliakim-Raz N; Shaw E; Tebé C; Wolkewitz M; Wiegand I; Grier S; Vank C; Cuperus N; Van den Heuvel L; Vuong C; MacGowan A; Leibovici L; Addy I; Pujol M;
Antimicrob Resist Infect Control; 2019; 8():198. PubMed ID: 31827779
[TBL] [Abstract][Full Text] [Related]
10. Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance.
Fernández-Barat L; Ferrer M; De Rosa F; Gabarrús A; Esperatti M; Terraneo S; Rinaudo M; Li Bassi G; Torres A
J Infect; 2017 Feb; 74(2):142-152. PubMed ID: 27865895
[TBL] [Abstract][Full Text] [Related]
11. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance.
Micek ST; Wunderink RG; Kollef MH; Chen C; Rello J; Chastre J; Antonelli M; Welte T; Clair B; Ostermann H; Calbo E; Torres A; Menichetti F; Schramm GE; Menon V
Crit Care; 2015 May; 19(1):219. PubMed ID: 25944081
[TBL] [Abstract][Full Text] [Related]
12. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
13. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for hospitalized patients with resistant or multidrug-resistant
Raman G; Avendano EE; Chan J; Merchant S; Puzniak L
Antimicrob Resist Infect Control; 2018; 7():79. PubMed ID: 29997889
[TBL] [Abstract][Full Text] [Related]
15. Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam.
Castaldo N; Givone F; Peghin M; Righi E; Sartor A; Bassetti M
J Glob Antimicrob Resist; 2017 Jun; 9():100-102. PubMed ID: 28495526
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan.
Leung CH; Wang NY; Liu CP; Weng LC; Hsieh FC; Lee CM
J Microbiol Immunol Infect; 2008 Dec; 41(6):491-8. PubMed ID: 19255693
[TBL] [Abstract][Full Text] [Related]
17. Microbiological and molecular studies on a multidrug-resistant Pseudomonas aeruginosa from a liver transplant patient with urinary tract infection in Egypt.
Shaaban MT; Abdel-Raouf M; Zayed M; Emara MA
BMC Microbiol; 2024 May; 24(1):184. PubMed ID: 38802754
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
Xipell M; Bodro M; Marco F; Martínez JA; Soriano A
Future Microbiol; 2017 Nov; 12():1323-1326. PubMed ID: 28980834
[TBL] [Abstract][Full Text] [Related]
19. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.
Neuner EA; Sekeres J; Hall GS; van Duin D
Antimicrob Agents Chemother; 2012 Nov; 56(11):5744-8. PubMed ID: 22926565
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
